Mint Ops Launches Its Fifth Division: Transition Consulting to Support Dental Clinic Owners Through Growth, Buy/Sell Decisions, and Operational Success




Mint Ops Launches Its Fifth Division: Transition Consulting to Support Dental Clinic Owners Through Growth, Buy/Sell Decisions, and Operational Success

Winnipeg, Manitoba, Jan. 02, 2026 (GLOBE NEWSWIRE) —

Mint Ops Logo

FOR IMMEDIATE RELEASE 

Winnipeg, MB – January 2nd, 2026 – Mint Ops, a national ecosystem of services supporting dental clinics across Canada, today announced the official launch of its fifth Division: Transition Consulting, a new division designed to help dental clinic owners navigate practice transitions, strategic growth, and long-term operational success. 

Transition Consulting expands Mint Ops’ ecosystem beyond software, staffing, marketing, imaging, and remote administration by introducing non-broker consulting services focused on practice transitions and operational strategy. The division supports dentists through major decisions including buying or selling a clinic, strengthening operations, increasing clinic value, and planning long-term growth. 

“Dentistry is changing fast, and clinic owners are being forced to make bigger decisions earlier than ever,” said Alex Zlatin, CEO of Mint Ops. “Transition Consulting exists to give owners clear, practical guidance – backed by real data, operational insight, and an ecosystem that can actually execute the plan.” 

To lead the new division, Mint Ops welcomes Dr. Dev Mangat, a dentist with extensive experience supporting clinic transitions and operational strategy across Canada. Dr. Mangat brings both clinical and advisory expertise to guide owners through complex and often emotional business decisions. 

“Clinic ownership is one of the most significant personal and financial investments a dentist will ever make,” said Dr. Mangat. “Transition Consulting provides owners with grounded, unbiased support – whether they are preparing to sell, planning to expand, or simply trying to run a better clinic.” 

Transition Consulting integrates directly into the broader Mint Ops ecosystem, which includes: 

• Practice Software and next-generation platforms currently in development, with previews planned at major industry shows in 2026 
• Grayscale Imaging, compatible with all TWAIN sensors, cameras and PMSs 
• Remote Administration, acting as an extension of front desk teams through outbound patient and insurance outreach 
• Recruitment Services, placing staff in both urban and remote communities across Canada 
• Marketing & Digital Services, including affordable subscription-based websites and fully transparent campaign reporting 

This launch marks a natural evolution of Mint Ops’ long-term mission to support dental clinics at every stage of ownership – from growth and operations to transition and succession planning. 

For more information about Transition Consulting, visit www.mintops.ca or contact: 

Media Contact 

Alex Zlatin 

CEO, Mint Ops 

Email: info@mintops.ca 

 

Mint Ops Logo

Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel




Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company’s litigation and intellectual property counsel.

Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the Company continues to advance and protect its proprietary pharmaceutical assets and development pipeline. Mr. Kasowitz is a highly experienced U.S. trial lawyer with decades of experience leading high-stakes intellectual property and complex commercial litigation in federal and state courts. His background includes representation in intellectual property disputes involving innovative technologies and life sciences.

Marc E. Kasowitz is a veteran American trial lawyer and the founding managing partner of Kasowitz LLP, a New York-based litigation firm he co-founded in 1993. He is widely recognized for his expertise in complex commercial litigation, having been named among the country’s top trial lawyers by Benchmark Litigation and honored as a Litigation Trailblazer by the National Law Journal. Mr. Kasowitz regularly serves as lead counsel in high-stakes disputes involving antitrust, securities, banking, and product liability matters, representing major corporate clients across a range of industries, and has earned recognition from Chambers USA, The Legal 500, and other legal ranking organizations for his trial experience and advocacy. For more information, click Kasowitz LLP

“Protecting and enforcing our intellectual property portfolio is central to Scilex’s long-term strategy and shareholder value,” said a spokesperson for Scilex. “The appointment of Marc Kasowitz and Kasowitz LLP strengthens our legal capabilities as we continue to commercialize our products and advance our late-stage pipeline.”

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido^® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB^®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba^®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

info@scilexholding.com

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido^® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB^®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba^®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, Scilex’s intellectual property goals and processes, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba^® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB^® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2026 Scilex Holding Company All Rights Reserved.

CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy




CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy

Engagement reinforces CDT’s strategy to unlock value from its solid-form asset portfolio

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 02, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has engaged NJS Foresight Bio-Advisory, LLC to identify, source and support the execution of out-licensing opportunities for selected assets within its solid-form patent portfolio. The engagement is intended to expand CDT’s commercial reach and accelerate potential licensing and royalty-based transactions.

NJS Foresight Bio-Advisory, LLC brings more than 20 years of out-licensing experience and has completed numerous successful licensing agreements across the biotechnology and pharmaceutical sectors. The firm’s principal, Dr. Nicholas J. Sarlis, brings over 25 years of clinical and pharmaceutical/biotechnology expertise to the role, including leadership of multidisciplinary teams advancing early and late-stage development programs, involvement in the successful launch of six global products, and direct participation in more than thirty clinical studies. He holds medical and doctoral degrees from the University of Athens and a PhD from Imperial College London, and is board certified in Internal Medicine in the United States. He is a Fellow of both the American College of Physicians and the Royal Society of Medicine.

CDT has built a portfolio of solid-form patents including cocrystals and salts that deliver enhanced physicochemical properties such as improved solubility, bioavailability and alternative delivery modes. These solid-forms also carry up to twenty years of patent protection, creating a pathway for partners to extend product lifecycles beyond traditional patent expiry.

The Company has been actively reviewing opportunities where marketed products face significant patent cliffs and where CDT has developed differentiated solid-forms of these active pharmaceutical ingredients. Industry data indicates a renewed period of investment activity in biopharma as companies respond to patent expirations, strategic consolidation and the adoption of AI-driven technologies. CDT believes these trends create a constructive environment for solid-form innovation and out-licensing.

“CDT continues to assess commercial pathways for its portfolio and sees strong potential for its solid-form assets to support lifecycle management strategies across the sector,” said Dr. Andrew Regan, Chief Executive Officer of CDT.

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. In parallel, CDT has implemented a cryptocurrency treasury reserve strategy, initially focused on Bitcoin (BTC), designed to diversify its capital allocation and strengthen its financial position. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors
CDT Equity Inc.
Info@cdtequity.com

As Flu Surge Continues, Polyrizon’s Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated




As Flu Surge Continues, Polyrizon’s Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Raanana, Israel, Jan. 02, 2026 (GLOBE NEWSWIRE) — As the 2025-2026 flu season intensifies across the United States, a mutated strain of influenza A is driving most cases, sparking concerns about a potentially tough winter ahead. According to the latest CDC estimates (as of late December 2025), flu has already caused at least 4.6 million illnesses, 49,000 hospitalizations, and 1,900 deaths nationwide.

Flu activity is rising sharply, with outpatient visits for influenza-like illness well above baseline in many states. Vaccination rates are lagging – over 47 million doses administered at pharmacies and offices so far, down about 3 million from last year – leaving more people vulnerable. While the vaccine remains the best defense, especially for preventing hospitalization, many choose not to vaccinate for various reasons, from personal beliefs to access issues.

According to the World Health Organization, which monitors the flu status all over the world, globally, influenza activity has increased since October 2025 with influenza A viruses predominant among the viruses detected globally. In many northern hemisphere countries, acute respiratory infection levels increase at this time of year. These increases are typically caused by seasonal epidemics of respiratory pathogens such as influenza, respiratory syncytial virus (RSV) and other common respiratory viruses.

This is where Israeli biotech company Polyrizon Ltd. (Nasdaq: PLRZ) offers a promising complementary approach. One of its leading product candidates, the PL-16 Viral Blocker, is a non-pharmaceutical hydrogel nasal spray based on the proprietary Capture & Contain (C&C) platform. It creates a thin, temporary physical barrier on the nasal mucosa that potentially capture and contains respiratory viruses – including influenza and common cold viruses – before they can infect cells.

Preclinical in-vitro studies have shown over 90% protection of cells from variable viral infections. Importantly, since the mechanism is purely physical, it doesn’t drive antiviral resistance, unlike some medications and vaccines.

On December 19, 2025, Polyrizon announced the submission of a Pre-Request for Designation to the FDA for PL-16 – a key step toward potential over-the-counter status as a product to reduce exposure to respiratory viruses. Designed to complement vaccines, masks, and hygiene, PL-16 could be particularly valuable during high-activity seasons, providing a simple, non-invasive layer of defense.

In a season marked by early surges and a dominant drifted strain, experts stress layered protection. For the millions vaccinated  and not vaccinated this year, innovations like Polyrizon’s PL-16 has the potential to offer an additional, drug-free tool to help stay ahead of the flu.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how innovations like Polyrizon’s PL-16 has the potential offer an additional, drug-free tool to help stay ahead of the flu. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty

Investor Relations

IR@polyrizon-biotech.com

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer




Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) —  Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones.

“We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes,” said Thomas Zindrick, President, CEO, and Chairman of the Board. “He brings extensive experience in oncology drug development of innovative therapies, including a proven track record of leading complex programs from early development through late-stage trials. Jason’s insight and disciplined approach to clinical execution will support our momentum as we approach key readouts in ovarian and lung cancer and work to unlock the full clinical and commercial potential of Olvi-Vec as a best-in-class immunotherapy.”

Dr. Litten is a seasoned biopharmaceutical executive with over 20 years of experience spanning academia, large pharmaceutical organizations, and innovative biotechnology companies. He has led the design, execution, and interpretation of Phase 1-4 clinical trials in liquid and solid tumors, with expertise across biologics, small molecules, and cellular therapies.

Most recently, Dr. Litten served as Chief Medical Officer at Chimeric Therapeutics, Ltd., where he advanced first-in-human cell therapy programs in brain, gastrointestinal, and hematologic cancers. Prior to that, he was Chief Medical Officer at Artiva Biotherapeutics, Inc., where he built and led clinical development, operations, regulatory affairs, quality, and medical affairs functions. Earlier in his career, Dr. Litten held senior leadership roles at Optera Therapeutics Corp., Juno Therapeutics, Inc., Clovis Oncology, Inc., and Amgen Inc., contributing to global development strategies for novel oncology therapeutics.

Dr. Litten earned an M.D. from Emory University School of Medicine and a B.S. in Finance and Economics from Cornell University. He completed postdoctoral training in Pediatric Hematology & Oncology at the University of Texas Southwestern Medical Center at Dallas and is licensed as a physician and surgeon in California.

“I am honored to join Genelux at such a pivotal time,” said Dr. Litten. “Olvi-Vec represents a compelling therapeutic platform with potential across multiple tumor types, and I look forward to working with the team to execute our clinical strategy, prepare for future regulatory interactions, and ultimately bring new options to patients facing difficult-to-treat cancers.

In connection with his appointment, Dr. Litten was granted an inducement award of a stock option to purchase 275,000 shares of common stock under Genelux’s 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), at an exercise price per share equal to the closing price of Genelux’s common stock on The Nasdaq Capital Market on the date of grant. The inducement award will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to Dr. Litten’s continued service relationship with the company through the applicable vesting dates.

About Genelux Corporation

Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician’s choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician’s choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux’s discovery and development efforts revolves around its proprietary CHOICE™ platform from which the company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on X @Genelux_Corp and on LinkedIn.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “believes,” “anticipates,” “expect,” “may,” “plan,” “look forward” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to Dr. Litten’s expected contribution to Genelux, Olvi-Vec’s development plans and the realization of Olvi-Vec’s full potential. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption “Risk Factors” in Genelux’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Genelux does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Investor Contact

Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com

Media Contact

Ashley Murphy
Precision AQ
ashley.murphy@precisionaq.com

Source: Genelux Corporation

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4196792-0f6a-456e-b165-1a9302b7e413

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET




BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET with Janet Legare, M.D., Professor in the Divisions of Genetics and Metabolism and Developmental Pediatrics and Rehabilitation Medicine in the Department of Pediatrics at the University of Wisconsin (UW) School of Medicine and Public Health and investigator in PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia. Dr. Legare also serves as director of both the Midwest Regional Bone Dysplasia Clinic and the Neuromotor Development Clinic, both affiliated with UW Health Kids.

Dr. Legare will provide an overview of achondroplasia, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating infigratinib as a treatment for skeletal dysplasia, including achondroplasia. Dr. Legare actively engages with leading professional organizations, including the American Academy of Pediatrics, the Society for Pediatric Research, the American College of Medical Genetics, Little People of America, and the International Skeletal Dysplasia Society, and holds an affiliate appointment in the Department of Neurological Surgery. Her clinical expertise spans the diagnosis, management, and long-term care of children with skeletal dysplasia.

In addition to Dr. Legare, executive members of the skeletal dysplasia program team will review the ongoing infigratinib clinical development program and discuss the ongoing Phase 3 PROPEL 3 study, for which topline results are expected in Q1 2026.

To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch




Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch

MONTREAL, Québec, Jan. 02, 2026 (GLOBE NEWSWIRE) — Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is pleased to announce preliminary success in the Québec provincial vape cartridge category launch. Estimated retail sales data indicates multiple leadership positions across the nascent category (for the months November and December 2025), with a 29.7% category share by retail sales value¹.

The success of the vape category launch also advanced Cannara to a #1 market share position by retail sales in Quebec for the month of December 2025, with a 14.7% share of cannabis retail sales in the province, a 100-basis point improvement month over month².

“The vape cartridge category launch in our home province of Québec has been a valuable opportunity to further expand our position as Canada’s #1 premium vape producer. With 5 of the 25 total SKUs approved, we successfully positioned our business for the largest product category launch in recent Canadian cannabis history, and I am encouraged at the strong initial consumer demand for our premium vapes,” said Zohar Krivorot, President & CEO of Cannara.

“Our highly advanced, vertically-integrated platform enabled the creation of truly premium, best-in-class products for Québec’s newly launched vape category. We are pleased to see strong reception to the launch of our first-ever rosin vape cartridge offerings, alongside our already nationally leading premium live resin vapes. We look forward to the continued consumer adoption of the category,” said Nicholas Sosiak, Chief Financial Officer of Cannara.

Cancellation and Re-Issuance of Previously Granted Stock Options

The Company also announces that, on December 31, 2025, its board of directors approved the cancellation and re-issuance of certain previously granted stock options to certain officers, directors and employees of the Company (the “Affected Options”) in connection with the administration of the Company’s equity compensation plans. The grant of the Affected Options was originally announced in news releases issued by the Company on September 1, 2025, and November 24, 2025.

The Company determined that, due to an administrative oversight, the issuance of the Affected Options resulted in the Company exceeding the limits permitted under its stock option plan (the “Stock Option Plan”) and restricted share unit compensation plan (the “RSU Plan”), each of which is currently a rolling plan permitting the issuance of up to 10% of the Company’s issued and outstanding common shares. The Affected Options were cancelled and are to be re-issued on January 2, 2026, with substantially the same terms and conditions, including the same exercise prices, with vesting schedules and expiry dates intended to remain unchanged and to continue as if originally granted.

A total of 544,600 stock options were cancelled and re-issued, including 515,000 stock options held by directors and officers of the Company. Amongst the cancelled and re-issued options held by insiders of the Company, 500,000 have an exercise price of $1.44 expiring on August 27, 2035, and 15,000 have an exercise price of $1.80 expiring on November 20, 2032. The cancellation and re-issuance were undertaken solely to address the administrative oversight and did not result in any net increase of stock options outstanding under the Stock Option Plan.

As disclosed in the Company’s management proxy circular dated December 18, 2025 (the “Circular”), in connection with a review of the Company’s security-based compensation arrangements and certain housekeeping changes undertaken to align the Stock Option Plan with governance practices applicable to senior Canadian stock exchanges, the Company is seeking shareholder approval at its annual general and special meeting to be held on January 29, 2026, to amend and convert the Stock Option Plan and the RSU Plan from rolling plans to fixed security-based compensation plans. The proposed amendments are intended to provide greater administrative clarity and facilitate ongoing compliance with plan limits.

Following implementation of the proposed amendments, the aggregate number of listed shares issuable under both plans will be fixed at 15% of the Company’s issued and outstanding listed shares as at the date of shareholder approval. The TSX Venture Exchange has provided conditional approval of the amended Stock Option Plan and amended RSU Plan, subject to shareholder approval. Copies of the amended plans are appended to the Circular.

The Circular and proxy-related materials are available on the Company’s website at https://www.cannara.ca/en/investor-area/ and under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Accelerated Vesting of RSUs

In addition, the Company announces that, on December 31, 2025, its board of directors approved the accelerated vesting of 15,000 restricted share units previously granted to the late Jack Kay, a former director and officer of the Company, effective December 31, 2025, to ensure compliance with the terms of the RSU Plan following his passing on November 8, 2025.

CONTACT

Nicholas Sosiak, CPA, CA Chief Financial Officer nick@cannara.ca

Zohar Krivorot  President & Chief Executive Officer  zohar@cannara.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

ABOUT CANNARA

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,650,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Leveraging Québec’s low electricity costs, Cannara’s facilities produce premium-grade cannabis products at an affordable price. For more information, please visit cannara.ca.

CAUTIONARY STATEMENT REGARDING “FORWARD-LOOKING” INFORMATION

This news release may contain “forward-looking information” within the meaning of Canadian securities legislation (“forward-looking statements”). These forward-looking statements are made as of the date of this MD&A and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. All statements other than statements of historical facts included in this document constitute forward-looking information, including but not limited to statements with respect to vape category launch in Quebec.

Forward-looking statements relate to future events or future performance and reflect Company management’s expectations or beliefs regarding future events and include, but are not limited to, the Company and its operations, its projections or estimates about its future business operations, its planned expansion activities, anticipated product offerings, the adequacy of its financial resources, the ability to adhere to financial and other covenants under lending agreements, future economic performance, and the Company’s ability to become a leader in the field of cannabis cultivation, production, and sales.

In certain cases, forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur” or “be achieved” or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including “may,” “future,” “expected,” “intends” and “estimates.” By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in, or implied by, such forward-looking information. These risks and uncertainties include, but are not limited to, the risk factors which are discussed in greater detail under “Risk Factors” in the Company’s AIF available on SEDAR+ at www.sedarplus.ca and under the “Investor Area” section of our website at https://www.cannara.ca/en/investor-area.

Other risks not presently known to the Company or that the Company believes are not significant could also cause actual results to differ materially from those expressed in its forward-looking statements. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, readers are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions were made in preparing the forward-looking information concerning the availability of capital resources, business performance, market conditions, as well as customer demand. Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein is provided as of the date hereof, and we do not undertake to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.
___________________________________________

¹ _{(Weedcrawler data, November 2025 to December 2025, https://weedcrawler.ca)}
² _{(Weedcrawler data, December 2025, https://weedcrawler.ca)}

Nova Leap Health Corp. Announces Promotion of Melissa Anderson to Senior Vice President, United States




Nova Leap Health Corp. Announces Promotion of Melissa Anderson to Senior Vice President, United States

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

HALIFAX, Nova Scotia, Jan. 02, 2026 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing provider of home-based and community-based care services in North America, is pleased to announce the promotion of Melissa Anderson from her role as Vice President, Operations (U.S.) to Senior Vice President (U.S.), effective January 1, 2026.

Ms. Anderson joined Nova Leap in 2018 and has played a central role in advancing the Company’s U.S. operations through disciplined execution, operational improvements, strengthened regional leadership structures, and EBITDA growth across the division. In her expanded role, Melissa will oversee Nova Leap’s U.S. home care operations, including strategic planning, operational performance, expansion into new states, and integration of new service lines, including the Company’s recently launched Care Management division.

“Melissa has demonstrated exceptional leadership and operational discipline throughout her tenure,” said Chris Dobbin, President & CEO. “Her promotion reflects both her strong performance and the increasing scale and complexity of our U.S. business. As we continue to grow through new locations, acquisitions and additional service lines across the continuum of care, Melissa’s leadership will be instrumental in driving execution and long-term value.”

“I am honoured to continue serving Nova Leap in this expanded capacity,” said Ms. Anderson. “Our U.S. team is deeply committed to delivering compassionate, high-quality care in communities across the country. I look forward to supporting our growth strategy and strengthening our operations to better serve our clients, families, and partners.”

Nova Leap continues to expand its footprint across the United States and Canada through disciplined growth, including targeted acquisitions and de novo expansion supported by scalable infrastructure.

About Nova Leap

Nova Leap is a healthcare services company delivering home-based and community-based care across North America. Through its network of local agencies, the Company provides personal care, dementia care, and companion services that enable individuals to live safely and independently at home. Nova Leap’s Care Management division extends its role across the continuum of care by offering coordinated, technology-enabled support that helps families navigate complex medical, cognitive, and social needs. Combining disciplined operations, data-driven decision-making, and compassionate service, Nova Leap is committed to improving outcomes for clients and communities while advancing sustainable, scalable models of community care.

FORWARD LOOKING INFORMATION:

Certain information in this press release may contain forward-looking statements, such as statements regarding future expansions, development of the Care Management division, anticipated geographic and organic growth, and potential acquisition opportunities. This information is based on current expectations and assumptions that are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are made as of the date of this release, and the Company assumes no obligation to update them except as required by applicable securities laws. Additional risk factors are detailed in the Company’s filings with Canadian securities regulators at www.sedarplus.com.

CAUTIONARY STATEMENT:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information:

Chris Dobbin, CPA, ICD.D
Director, President and CEO
P: 902-401-9480    
E:cdobbin@novaleaphealth.com

Mesoblast Announces Changes to Board of Directors’ Leadership Roles




Mesoblast Announces Changes to Board of Directors’ Leadership Roles

NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company’s evolution to a revenue-generating commercial company.

Having presided during the most transformational period for the company with its first U.S. Food & Drug Administration (FDA) approval and successful product commercialization, Ms Jane Bell will retire from her role as Chair and will remain on the Board as a non-executive director. The Board has unanimously appointed Mr Philip Facchina to the role of non-executive Chair and Ms Lyn Cobley as Chair of the Audit and Risk Committee. Mr William Burns remains as Mesoblast Vice-Chair and Chair of the Nomination and Remuneration Committee.

Incoming Chair Mr Facchina said, “The Board is deeply grateful and acknowledges Ms Bell for her dedicated service as Chair of Mesoblast during a critical period of the Company’s transformation from development to commercialization.”

Mr Facchina joined the Mesoblast board in March 2021 and has over forty years of experience in corporate strategy, finance, and business development across several industries, including healthcare. Ms Cobley joined the Mesoblast board in April 2025 and has extensive corporate finance and governance experience at some of the largest institutions globally and has a strong background in strategy and leadership, and working in highly regulated industries.

“These changes reflect our focus on maintaining a high performing, engaged Board with the right mix of expertise and fresh perspectives,” said Ms Bell, outgoing Chair of the Board. “I look forward to supporting Phil and Lyn and the rest of the board as we continue to execute on our long-term strategy for shareholders and other stakeholders.”

Today’s announced changes follow a periodic review of Board composition, committee assignments, and leadership structure, which the Board undertakes as part of regular governance process. Our commitment to sound governance ensures the right blend of expertise, tenure and renewal. Mesoblast expects to further strengthen its U.S. commercial expertise in the company in the next twelve months in line with stated commitment to maximizing commercial delivery and shareholder value.

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil^® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil^® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors
Paul Hughes
T: +61 3 9639 6036
Media – Global	Media – Australia
Allison Worldwide	BlueDot Media
Emma Neal	Steve Dabkowski
T: +1 603 545 4843	T: +61 419 880 486
E: emma.neal@allisonworldwide.com	E: steve@bluedot.net.au

Best CBD Gummies 2026 Consumer Report: Full Spectrum Formulations, Lab Testing Standards, and State Legal Requirements Examined in Consumer Wellness Category Analysis




Best CBD Gummies 2026 Consumer Report: Full Spectrum Formulations, Lab Testing Standards, and State Legal Requirements Examined in Consumer Wellness Category Analysis

As January 2026 wellness searches peak, this consumer education analysis examines how informed buyers evaluate CBD gummies for sleep and stress — comparing spectrum types, verifying third-party lab testing, navigating state-by-state legal realities, and understanding drug test considerations, with Calm Nature CBD Gummies cited as one full spectrum category example

LOS ANGELES, CA, Jan. 01, 2026 (GLOBE NEWSWIRE) — Defining “Best” in This Analysis: This article uses “best” to describe evaluation criteria and consumer search behavior, not to declare product superiority. The goal is to help readers understand what factors matter when comparing CBD gummies — not to rank or endorse specific products.

Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. CBD products are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Always consult a qualified healthcare professional before starting any new supplement. CBD product legality varies by jurisdiction — verify current federal and state laws in your area before purchasing.  This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented.

Why “Best CBD Gummies 2026” Has Become January’s Most Searched Wellness Term

January consistently represents the highest annual surge in CBD-related searches, driven by New Year routine resets, wellness goals, and increased interest in non-prescription supplement categories.

Something predictable happens every January. Millions of people who spent December indulging, stressing, and losing sleep suddenly decide that this year will be different. The wellness industry calls it the “New Year reset” — that window between January 1st and mid-February when supplement searches spike, gym memberships surge, and people finally act on health intentions they have been putting off.

CBD gummies sit at the intersection of several powerful January search trends. Consumer interest in natural wellness options, plant-based supplements, and non-prescription approaches to daily routines has grown significantly. People searching “best CBD gummies 2026” are typically looking for a framework to evaluate their options — not marketing claims.

Here is the challenge: The CBD market has exploded with choices, and most people have no systematic way to compare products. They have seen the ads. They are curious. Now they need real evaluation criteria before making a decision.

This analysis examines the factors informed consumers typically consider when comparing CBD gummies, using Calm Nature CBD Gummies as one example of how companies in the full spectrum category position their products.

View the current Calm Nature CBD Gummies offer (official Calm Nature page)

The 2026 CBD Gummies Evaluation Framework: What Informed Buyers Consider

Before examining any specific product, understanding the evaluation criteria that informed consumers use provides the foundation for comparison shopping.

Methodology Note: This analysis reflects publicly available information, regulatory guidance, published research, and common evaluation criteria used by informed consumers when comparing hemp-derived CBD gummy products. No products were tested, ranked, or endorsed. Company descriptions are presented as stated by the brands themselves and are included for illustrative, category-context purposes only.

The Five Factors Buyers Typically Evaluate

1. Spectrum Type (Full, Broad, or Isolate)

This represents the primary formulation distinction. Full spectrum products contain the range of cannabinoids naturally present in hemp, including trace THC within legal limits. Broad spectrum removes THC while retaining other cannabinoids. Isolate contains only CBD. Consumer preference varies based on individual priorities and circumstances.

2. Extraction Method

CO2 extraction is generally discussed as a cleaner method that avoids residual solvents. Ethanol and hydrocarbon methods are also used in the industry with varying quality outcomes depending on execution.

3. Third-Party Lab Testing (COA Verification)

Certificates of Analysis from independent laboratories verify that CBD content matches labels, THC stays within legal limits, and products are free from contaminants. This documentation helps consumers evaluate product claims.

4. Legal Compliance

Hemp-derived CBD containing less than 0.3% THC is federally legal under the 2018 Farm Bill, but state regulations vary. Understanding jurisdictional requirements helps consumers avoid compliance issues.

5. Company Transparency

Clear contact information, published policies, and accessible customer service indicate established business operations.

Evaluation Factor	What Buyers Look For	Common Concerns
Spectrum Type	Clearly labeled formulation	Vague “hemp extract” without specification
Extraction	Disclosed extraction method	No method information provided
Lab Testing	Accessible COAs with batch numbers	Claims without documentation
Legal Status	Farm Bill compliance stated	No THC content disclosure
Company Info	Physical address, phone, email	Only web forms, no direct contact

Consumer Interest in CBD Gummies for Sleep: What’s Driving the Conversation

Consumer interest in CBD gummies related to sleep and nighttime routines has increased significantly. This section examines what’s driving that interest and what the current research landscape looks like.

Why Consumers Are Exploring This Category

The growth in searches for CBD gummies related to sleep reflects broader consumer interest in non-prescription wellness approaches. Many people are curious about plant-based options as part of their nighttime routines.

It is important to note: Consumer interest does not establish efficacy. CBD gummies are supplements, not sleep medications, and have not been approved by the FDA for treating sleep disorders or any medical condition.

What Current Research Shows (And Doesn’t Show)

A 2019 study published in The Permanente Journal (Shannon S, Lewis N, Lee H, Hughes S. “Cannabidiol in Anxiety and Sleep: A Large Case Series.” Perm J. 2019;23:18-041) examined CBD in 72 adults and reported that sleep scores improved in 66.7% of participants during the first month.

Critical context this study does NOT establish:

• It was observational, not a controlled clinical trial
• Participants were also receiving psychiatric treatment
• It did not evaluate any consumer CBD gummy products
• Results fluctuated over time
• It does not support claims about specific products like Calm Nature

This research is cited here to illustrate the type of preliminary inquiry occurring in this space — not to imply that CBD gummies produce predictable outcomes for consumers.

The Realistic Perspective

Consumer interest in CBD gummies for nighttime routines has grown, driven by broader conversations around relaxation and non-prescription wellness approaches. Current research in this area remains exploratory and does not establish CBD gummies as a treatment for sleep disorders or medical conditions.

Individual experiences with CBD vary significantly. What one person finds useful, another may not notice at all. Consumers exploring this category should maintain realistic expectations and consult healthcare providers for sleep concerns.

Consumer Interest in CBD Gummies for Stress: Understanding the Category

Similar growth in consumer searches has occurred around CBD and stress-related topics. Understanding what’s driving this interest — and what CBD gummies can and cannot do — helps set appropriate expectations.

What’s Driving Consumer Curiosity

Many people are exploring plant-based wellness options as part of their daily routines. The CBD category has attracted interest from consumers curious about non-prescription approaches to general wellness.

Important distinction: Consumer curiosity does not establish product efficacy. As noted earlier, CBD gummies are supplements that have not been evaluated by the FDA for treating anxiety, stress disorders, or any medical condition.

The Critical Distinction

Everyday stress — work deadlines, traffic, family obligations — represents normal human experience that everyone navigates.

Clinical anxiety — persistent, excessive worry that interferes with daily functioning — requires professional evaluation and treatment.

CBD products occupy the wellness supplement space, not the pharmaceutical treatment space. Anyone experiencing persistent anxiety that affects daily life should consult a mental health professional rather than self-treating with supplements.

What Consumers Should Understand

Consumer interest in CBD gummies has increased, driven by broader conversations around relaxation, daily routines, and non-prescription wellness approaches. As noted earlier, current research remains exploratory and does not establish CBD gummies as a treatment for anxiety or stress disorders.

The same Permanente Journal study mentioned earlier found anxiety scores decreased in participants, but those participants were also receiving psychiatric treatment, making it impossible to isolate CBD’s specific contribution. This study did not evaluate consumer gummy products.

Full Spectrum vs. Broad Spectrum vs. Isolate: Understanding the Differences

Understanding spectrum differences helps consumers identify which formulation type aligns with their preferences and circumstances.

Full Spectrum CBD

Full spectrum products contain the range of cannabinoids naturally present in hemp plants, including trace THC within the legal 0.3% threshold, along with other cannabinoids, terpenes, and flavonoids.

The “Entourage Effect” Concept:

Some researchers have theorized that cannabinoids may work differently when present together versus in isolation. This concept, while discussed in the industry, has not been definitively established through clinical research.

Considerations for Consumers:

• Contains trace THC (within legal limits)
• May not be appropriate for those with drug testing concerns
• Legal status varies in some states with stricter THC requirements

Broad Spectrum CBD

Broad spectrum undergoes additional processing intended to remove THC while retaining other cannabinoids.

Considerations for Consumers:

• Marketed as THC-free (verification via COA recommended)
• May appeal to those with drug testing considerations
• Processing may affect some plant compounds

CBD Isolate

Isolate contains only cannabidiol with other plant compounds removed.

Considerations for Consumers:

• Contains no THC
• Most predictable single-compound profile
• Lacks other cannabinoids present in full/broad spectrum

Spectrum Comparison

Factor	Full Spectrum	Broad Spectrum	Isolate
THC Content	<0.3%	0% (claimed)	0%
Other Cannabinoids	Present	Partial	None
Processing Level	Minimal	Moderate	Maximum

CBD Safety Profile: What Regulatory Bodies Have Stated

Understanding what regulatory and health organizations have said about CBD safety helps consumers evaluate the category with appropriate context.

World Health Organization Assessment

The World Health Organization’s Expert Committee on Drug Dependence published a critical review of cannabidiol in 2018, stating that CBD “is generally well tolerated with a good safety profile” and that “to date, there is no evidence of recreational use of CBD or any public health-related problems associated with the use of pure CBD.”

This assessment relates to CBD as a compound — not to specific consumer products, which vary in quality, formulation, and manufacturing standards.

FDA Position

The FDA has stated that existing regulatory frameworks for foods and dietary supplements are not appropriate for cannabidiol, and the agency continues to evaluate potential pathways. CBD products sold as supplements have not been evaluated by the FDA for safety or efficacy.

What This Means for Consumers

While CBD as a compound has been assessed favorably by international health bodies, consumer products vary significantly in quality. Third-party testing verification, company transparency, and realistic expectations remain important factors in consumer decision-making.

Drug Testing: The Complete Reality Check

This section contains critical information for consumers subject to drug testing.

No full spectrum CBD product can guarantee drug test outcomes. Even hemp-derived products may contain trace THC within legal limits, and individual metabolism, frequency of use, and testing sensitivity vary.

How Drug Tests Work

Standard employment drug screenings test for THC metabolites (THC-COOH), not CBD. Common cutoff thresholds are 50 ng/mL, though some employers use more sensitive thresholds.

CBD itself does not trigger positive drug tests. However, full spectrum CBD products contain trace THC within legal limits, creating theoretical detection risk.

Factors That May Influence Results

• Product type: Full spectrum contains trace THC; isolate does not
• Usage patterns: Frequency and amount of consumption
• Individual metabolism: How quickly the body processes compounds
• Test sensitivity: Different thresholds across testing protocols
• Body composition: THC metabolites are fat-soluble

What Calm Nature States (And What Consumers Should Understand)

According to Calm Nature’s marketing materials, the company describes their products as processed through “triple filtration technology.”

Critical consumer understanding: No full spectrum CBD product can guarantee drug test outcomes. Marketing claims about drug tests should be evaluated against the scientific reality that trace THC exists in full spectrum products, individual factors vary significantly, and no supplement company can control testing outcomes.

Consumers subject to drug testing should:

• Consider broad spectrum or isolate products instead
• Consult with employers about CBD policies
• Request COA documentation showing actual THC content
• Make informed decisions based on personal risk assessment

State-by-State Legal Realities for 2026

Understanding the legal landscape helps consumers verify compliance before purchasing.

Federal Status

Hemp-derived CBD products containing less than 0.3% THC by dry weight are federally legal under the Agriculture Improvement Act of 2018 (Farm Bill). This federal framework does not override state-level restrictions.

Because federal and state rules continue to evolve — including proposed and approved changes that may affect how hemp-derived products are defined and shipped — consumers should verify the most current requirements in their jurisdiction before ordering.

States With Stricter or Evolving Requirements

Idaho — Maintains a 0% THC requirement per state policy. Standard full spectrum products typically do not comply with Idaho law.

Nebraska — Has maintained stricter interpretations historically, with ongoing legislative activity. Consumers should verify current status through official state resources.

South Dakota — State hemp product policies continue to evolve. Consumers should confirm current rules directly through official state resources before purchasing.

Some states maintain stricter requirements or have evolving enforcement and legislative activity; consumers should confirm current rules directly through official state resources.

Additional Considerations

• Some states require CBD purchase from licensed retailers
• Workplace policies may prohibit CBD use regardless of legality
• International travel with CBD may create complications

Consumer Responsibility

CBD gummies derived from hemp containing less than 0.3% THC are legal in most U.S. jurisdictions. Consumers are responsible for verifying compliance with their specific state laws, employer policies, and any other applicable requirements.

What This Analysis Does Not Do

This article does not test products, provide medical guidance, predict individual outcomes, or recommend one CBD gummy over another. It is designed to help readers understand how informed consumers evaluate products in this category — not to tell anyone what they should purchase.

Calm Nature CBD Gummies: How One Company Positions in This Category

When comparing CBD products, examining how companies describe their offerings helps consumers understand category positioning. Calm Nature CBD Gummies represents one example of how companies in the full spectrum category present their products.

Company-Stated Formulation Details

According to Calm Nature’s official website, the company describes their gummies as featuring:

• Full spectrum cannabinoid formulation
• Cold-pressed and unrefined CBD extraction
• CO2 extraction technology
• “Triple filtration technology” for THC processing

The company describes its gummies as designed for convenient daily use and highlights its extraction and filtration process in its marketing materials.

These descriptions represent company marketing claims. Consumers should verify specific claims through third-party documentation when available. As with any supplement, these descriptions reflect how the company presents its product and should be evaluated alongside independent verification, regulatory guidance, and individual consumer priorities.

Availability Information

According to information published by the company, Calm Nature offers multi-bottle purchase options with variable pricing and shipping terms. Current availability, package configurations, and refund policies are listed on the official Calm Nature website and may change without notice.

The company states a 60-day refund window with customer service contact required. Consumers should verify current terms directly before purchasing.

View the current Calm Nature CBD Gummies offer (official Calm Nature page)

What Manufacturers Provide on Product Labels

CBD gummy serving information is provided by manufacturers on product labels. Consumers typically review these instructions alongside healthcare guidance when evaluating whether a supplement fits their routine.

The FDA has not established standardized daily intake levels for CBD supplements. Serving sizes vary by product and manufacturer.

General Consumer Approaches:

Many consumers start with manufacturer-suggested servings and observe their individual response over time. Because CBD supplements are not standardized like pharmaceuticals, individual approaches vary.

Healthcare Consultation:

Anyone with health conditions, taking medications, or with specific concerns should consult healthcare providers before adding any supplement to their routine. CBD may interact with certain medications.

Who Might Explore This Category (And Who Should Consider Alternatives)

Rather than universal recommendations, a self-assessment approach helps consumers determine whether CBD gummies align with their specific situations.

Consumers Who Typically Explore Full Spectrum CBD Gummies:

• Those specifically interested in full spectrum formulations
• People who prefer the gummy supplement format
• Consumers who have verified legal compliance in their jurisdiction
• Those without drug testing concerns (or who have evaluated their specific situation)
• People with realistic expectations about supplements

Consumers Who May Want to Consider Alternatives:

• Those with strict drug testing requirements (consider isolate products)
• People in states with 0% THC requirements (full spectrum may not comply)
• Anyone seeking treatment for medical conditions (consult healthcare providers)
• Consumers taking medications (potential interactions — consult providers)
• Those who need faster onset (oils absorb differently than gummies)

Questions for Self-Assessment:

1. What am I hoping to explore with CBD supplements?
2. Do I have any drug testing considerations?
3. Have I verified CBD legality in my state?
4. Have I consulted with my healthcare provider?
5. Are my expectations realistic about what supplements can and cannot do?

How to Evaluate CBD Product Quality

With many CBD products available, systematic evaluation helps consumers compare options.

Step 1: Review Third-Party Lab Documentation

Certificates of Analysis from independent laboratories help verify:

• CBD content relative to label claims
• THC content within legal limits
• Absence of contaminants (heavy metals, pesticides, solvents)

COAs should be current, batch-specific, and from named laboratories.

Step 2: Evaluate Transparency

Quality indicators include:

• CBD content clearly stated per serving
• Spectrum type clearly labeled
• Hemp source disclosed
• Complete ingredient list available
• Company contact information accessible

Step 3: Research Company Background

Consumers often review:

• Business history and establishment
• Customer service accessibility
• Return policy clarity
• Third-party reviews across platforms

Step 4: Consider Value Relative to Market

CBD gummy pricing varies across the market. Extremely low pricing may indicate quality concerns. High pricing does not guarantee quality. Consumers typically evaluate value relative to verification, transparency, and company reputation rather than price alone.

Common Questions About CBD Gummies

Is Full Spectrum CBD Legal in All States in 2026?

Hemp-derived CBD products containing less than 0.3% THC are federally legal under the 2018 Farm Bill. However, some states maintain stricter requirements. Idaho requires 0% THC. Nebraska and South Dakota have evolving legislative and enforcement activity. Because federal and state rules continue to change, consumers should verify current requirements through official state resources before purchasing.

Do CBD Gummies Interact With Prescription Medications?

CBD may interact with certain medications, particularly those metabolized by the cytochrome P450 enzyme system. Anyone taking prescription medications should consult their healthcare provider before using CBD supplements. This is especially important for blood thinners, heart medications, immunosuppressants, and other drugs where interactions could affect efficacy or safety.

How Are CBD Gummies Different From CBD Oils or Capsules?

The primary differences relate to absorption and convenience. Gummies require digestion before cannabinoids reach the bloodstream, typically taking 30-60 minutes or longer. Sublingual oils are held under the tongue for faster absorption. Capsules function similarly to gummies in terms of digestion time. Gummies offer pre-measured servings and a familiar format, while oils allow more flexible serving adjustments.

Additional Frequently Asked Questions

Are CBD gummies legal in 2026?

Hemp-derived CBD products containing less than 0.3% THC are federally legal under the 2018 Farm Bill. Some states maintain stricter requirements. Consumers should verify their specific state’s regulations.

Will CBD gummies produce intoxicating effects?

CBD is non-psychoactive. Full spectrum products contain trace THC within legal limits (under 0.3%), which is not sufficient to produce intoxicating effects for most people.

How long before effects might be noticed?

Gummies require digestion before absorption, typically 30-60 minutes or longer depending on individual factors. This varies significantly between individuals.

Can CBD gummies be taken with medications?

CBD may interact with certain medications. Anyone taking prescription medications should consult their healthcare provider before using CBD supplements.

Will CBD gummies affect drug tests?

No full spectrum CBD product can guarantee drug test outcomes. Full spectrum products contain trace THC. Consumers with drug testing concerns should consider isolate products and consult with employers about policies.

What is the difference between hemp gummies and CBD gummies?

“Hemp gummies” may refer to products made with hemp seed oil (no cannabinoids) or CBD products from hemp. Consumers should verify CBD content is specifically stated.

Final Perspective: Evaluating CBD Gummies for 2026

As consumers evaluate CBD options heading into 2026, the market offers extensive choices — making systematic evaluation more valuable than ever.

What This Analysis Covered

This consumer category analysis examined the evaluation criteria informed buyers typically consider when comparing CBD gummies:

• Spectrum type differences and implications
• Lab testing verification importance
• Legal compliance considerations
• Drug testing realities
• Company transparency indicators

Calm Nature CBD Gummies was referenced as one example of how companies in the full spectrum category position their products — not as a ranked recommendation.

The Consumer’s Role

The “best” CBD gummy depends entirely on individual circumstances, preferences, and priorities. Factors like drug testing requirements, state regulations, healthcare considerations, and personal preferences all influence which products may be appropriate for specific consumers.

Realistic Expectations

CBD gummies are supplements in a category that has attracted significant consumer interest. They are not medications, have not been FDA-approved for treating any condition, and individual experiences vary widely.

Consumers exploring this category benefit from:

• Realistic expectations about supplements
• Verification of legal compliance
• Healthcare consultation when appropriate
• Systematic product evaluation
• Understanding that individual results vary

View the current Calm Nature CBD Gummies offer (official Calm Nature page)

Contact: care@calmnaturecbd.com

Disclaimers

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The FDA has stated that existing regulatory frameworks for foods and dietary supplements are not appropriate for cannabidiol, and the agency continues to evaluate potential pathways. Always consult your physician before starting any new supplement.

Legal Disclaimer: CBD product legality varies by jurisdiction. Hemp-derived CBD containing less than 0.3% THC is federally legal under the 2018 Farm Bill. Some states maintain stricter requirements including Idaho’s 0% THC threshold. Federal and state regulations continue to evolve and may affect how hemp-derived products are defined and sold. Users are responsible for verifying compliance with all applicable current laws. This article does not constitute legal advice.

Medical Disclaimer: This article is educational and does not constitute medical advice. CBD supplements are not medications. Anyone with health conditions, taking medications, pregnant or nursing, should consult healthcare providers before using CBD supplements.

Drug Testing Disclaimer: No full spectrum CBD product can guarantee drug test outcomes. Even hemp-derived products may contain trace THC within legal limits, and individual metabolism, frequency of use, and testing sensitivity vary. Consumers subject to drug testing should evaluate their specific circumstances carefully.

Results Disclaimer: Individual experiences vary based on numerous factors. CBD supplements should not be expected to produce predictable outcomes. Nothing in this article guarantees specific results.

Affiliate Disclosure: This article contains affiliate links. Purchases through these links may result in commission at no additional cost to you. This compensation does not influence editorial content.

Research Citations: Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041. doi:10.7812/TPP/18-041. This study is cited for general market context only and did not evaluate Calm Nature or any consumer CBD gummy product.

World Health Organization. Cannabidiol (CBD) Critical Review Report. Expert Committee on Drug Dependence, Fortieth Meeting, Geneva, 4-7 June 2018. This assessment relates to CBD as a compound and does not constitute endorsement of any consumer product.

Consumer Wellness Category Analysis Published: January 2026

CONTACT: Contact: care@calmnaturecbd.com